PolyNovo Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Swami Raote

Chief executive officer

AU$1.5m

Total compensation

CEO salary percentage	46.4%
CEO tenure	2.3yrs
CEO ownership	n/a
Management average tenure	1.2yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Swami Raote's remuneration changed compared to PolyNovo's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$2m	AU$707k	AU$5m
Mar 31 2024	n/a	n/a	AU$3m
Dec 31 2023	n/a	n/a	AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$2m	AU$617k	-AU$5m

Compensation vs Market: Swami's total compensation ($USD990.35K) is about average for companies of similar size in the Australian market ($USD1.10M).

Compensation vs Earnings: Swami's compensation has been consistent with company performance over the past year.

CEO

Swami Raote

2.3yrs

Tenure

AU$1,523,944

Compensation

Mr. Swami Raote, B. Pharmacy, M.B.A, serves as Director at PolyNovo Limited since September 2022. He serves Entrepreneurs in Residence at DigitalDx Ventures. He serves as Chief Executive Officer at PolyNov...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Swami Raote	CEO & Director	2.3yrs	AU$1.52m	no data
Jan-Marcel Gielen	Chief Financial Officer	5.9yrs	AU$371.95k	0.093% A$ 1.3m
David McQuillan	Chief Technical & Scientific Officer	2.2yrs	AU$538.84k	0.097% A$ 1.3m
Philip Scorgie	Chief Information Officer	1.5yrs	AU$329.02k	no data
Lior Harel	General Counsel & Company Secretary	less than a year	no data	no data
Ingrid Anderson	Chief People Officer	less than a year	no data	no data
Edward Graubart	President of North America	5.2yrs	no data	no data
Ahmed Hassan	Chief Manufacturing & Supply Chain Officer	less than a year	no data	no data
Joseph Amaral	Chief Medical Officer	less than a year	no data	no data
David Morris	President of Asia Pacific	less than a year	no data	no data

1.2yrs

Average Tenure

Experienced Management: PNV's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Swami Raote	CEO & Director	2.2yrs	AU$1.52m	no data
Robyn Elliott	Independent Non-Executive Director	5.1yrs	AU$95.00k	0.011% A$ 148.1k
David Williams	Independent Non-Executive Chairman	10.8yrs	AU$139.43k	3.1% A$ 42.4m
Andrew Lumsden	Independent Non-Executive Director	3.4yrs	AU$95.00k	0.014% A$ 198.0k
Leon Hoare	Independent Non-Executive Director	8.8yrs	AU$95.02k	0.16% A$ 2.2m
Christine Emmanuel-Donnelly	Independent Non-Executive Director	4.5yrs	AU$95.00k	0.039% A$ 536.1k

4.8yrs

Average Tenure

Experienced Board: PNV's board of directors are considered experienced (4.8 years average tenure).

PolyNovo Management

Management criteria checks 3/4

Key information

Recent management updates

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Insufficient new directors

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Recent updates

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 20% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: EPS: AU$0.008 (vs AU$0.007 loss in FY 2023)

Now 23% undervalued

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

Now 21% undervalued

Now 20% undervalued

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Forecast breakeven date pushed back to 2024

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.007 loss in FY 2021)

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

Independent Non-Executive Chairman recently bought AU$434k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Forecast to breakeven in 2023

PolyNovo Limited Provides an Update on its Hernia Device

Non-Executive Independent Director recently sold AU$571k worth of stock

Independent Non-Executive Chairman recently bought AU$721k worth of stock

PolyNovo Announces It has Received Final Independent Review Board

Revenue beats expectations

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in 1H 2020)

New 90-day low: AU$2.42

New 90-day high: AU$3.55

PolyNovo Limited Announces the Breast Device Development Program with Establishment Labs

Non-Executive Independent Director recently sold AU$1.2m worth of stock

PolyNovo Limited Announces US FDA Approves Pivotal Trial IDE

New 90-day high: AU$3.03

New 90-day high: AU$2.74

New 90-day high: AU$2.38

PolyNovo Appoints Innova Medical Oy to Sell Novosorb® BTM in Finland

Independent Non-Executive Chairman recently bought AU$1.0m worth of stock

New 90-day low - AU$2.02

Full year earnings released - AU$0.0063 loss per share

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure